OFIX icon

Orthofix Medical

16.02 USD
-0.29
1.78%
Updated Apr 1, 2:42 PM EDT
1 day
-1.78%
5 days
-2.79%
1 month
-5.65%
3 months
-7.18%
6 months
4.77%
Year to date
-7.18%
1 year
13.94%
5 years
-38.60%
10 years
-57.47%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 40

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

6% more capital invested

Capital invested by funds: $543M [Q3] → $577M (+$34M) [Q4]

4% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 24

0% more funds holding

Funds holding: 149 [Q3] → 149 (+0) [Q4]

0% more call options, than puts

Call options by funds: $7K | Put options by funds: $7K

4.55% less ownership

Funds ownership: 91.04% [Q3] → 86.49% (-4.55%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
37%
upside
Avg. target
$23
44%
upside
High target
$24
50%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Caitlin Burrows
46% 1-year accuracy
12 / 26 met price target
50%upside
$24
Buy
Maintained
26 Feb 2025
Roth MKM
Jason Wittes
43% 1-year accuracy
9 / 21 met price target
37%upside
$22
Buy
Reiterated
26 Feb 2025

Financial journalist opinion

Based on 4 articles about OFIX published over the past 30 days

Neutral
Business Wire
1 week ago
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT.
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
Neutral
GlobeNewsWire
2 weeks ago
Kuehn Law Encourages Investors of Orthofix Medical Inc. to Contact Law Firm
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders.
Kuehn Law Encourages Investors of Orthofix Medical Inc. to Contact Law Firm
Neutral
Business Wire
2 weeks ago
Orthofix Announces Appointment of Vickie Capps to Board of Directors
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. “Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously.
Orthofix Announces Appointment of Vickie Capps to Board of Directors
Neutral
Business Wire
4 weeks ago
Orthofix to Participate in the 37th Annual Roth Conference
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conference in Dana Point, CA. Management is scheduled to present on Monday, March 17, 2025 at 8:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.com. Internet Posti.
Orthofix to Participate in the 37th Annual Roth Conference
Neutral
Seeking Alpha
1 month ago
Orthofix Medical Inc. (OFIX) Q4 2024 Earnings Call Transcript
Orthofix Medical Inc. (OFIX) Q4 2024 Earnings Call Transcript
Orthofix Medical Inc. (OFIX) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Orthofix (OFIX) Q4 Earnings Lag Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago.
Orthofix (OFIX) Q4 Earnings Lag Estimates
Neutral
Business Wire
1 month ago
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 202.
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
Neutral
Business Wire
1 month ago
Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 9:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.co.
Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference
Negative
Benzinga
1 month ago
Top 2 Health Care Stocks That May Crash In February
As of Feb. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Top 2 Health Care Stocks That May Crash In February
Neutral
Business Wire
2 months ago
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations.
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results
Charts implemented using Lightweight Charts™